Literature DB >> 14644846

Seronegative antiphospholipid syndrome.

G R V Hughes1, M A Khamashta.   

Abstract

Mesh:

Substances:

Year:  2003        PMID: 14644846      PMCID: PMC1754381          DOI: 10.1136/ard.2003.006163

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  6 in total

Review 1.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.

Authors:  W A Wilson; A E Gharavi; T Koike; M D Lockshin; D W Branch; J C Piette; R Brey; R Derksen; E N Harris; G R Hughes; D A Triplett; M A Khamashta
Journal:  Arthritis Rheum       Date:  1999-07

2.  Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.

Authors:  G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

3.  The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.

Authors:  M L Bertolaccini; T Atsumi; A Escudero Contreras; M A Khamashta; G R Hughes
Journal:  J Rheumatol       Date:  2001-12       Impact factor: 4.666

Review 4.  Hughes syndrome crosses boundaries.

Authors:  Guillermo Ruiz-Irastorza; Munther A Khamashta; Graham R V Hughes
Journal:  Autoimmun Rev       Date:  2002-02       Impact factor: 9.754

5.  Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome.

Authors:  M L Bertolaccini; B Roch; O Amengual; T Atsumi; M A Khamashta; G R Hughes
Journal:  Br J Rheumatol       Date:  1998-11

6.  Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.

Authors:  E N Harris; A E Gharavi; M L Boey; B M Patel; C G Mackworth-Young; S Loizou; G R Hughes
Journal:  Lancet       Date:  1983-11-26       Impact factor: 79.321

  6 in total
  45 in total

1.  Hughes syndrome (the antiphospholipid syndrome): a disease of our time.

Authors:  Graham R V Hughes
Journal:  Inflammopharmacology       Date:  2010-12-05       Impact factor: 4.473

2.  Thin-layer chromatography immunostaining in detecting anti-phospholipid antibodies in seronegative anti-phospholipid syndrome.

Authors:  F Conti; C Alessandri; M Sorice; A Capozzi; A Longo; T Garofalo; R Misasi; D Bompane; G R V Hughes; M A Khamashta; G Valesini
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

3.  An aspirin responsive non-progressive chronic chorea.

Authors:  J A Oates; J K Lovett; N J Gutowski
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

4.  Livedo reticularis and related disorders.

Authors:  Steven M Dean
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-04

5.  Severe limb necrosis: primary thrombotic microangiopathy or "seronegative" catastrophic antiphospholipid syndrome? A diagnostic dilemma.

Authors:  I Lazurova; Z Macejova; Z Tomkova; F Remenar; A Boor; J Lazur; R Roland; J Rovensky; R A Asherson
Journal:  Clin Rheumatol       Date:  2007-01-26       Impact factor: 2.980

6.  An extraordinary case of recurrent stroke, disseminated thrombosis and endocarditis.

Authors:  Liza Mariam Thomas; Niaz Ahmed Shaikh; Ranjana Pradeep
Journal:  BMJ Case Rep       Date:  2018-06-04

7.  Familial primary antiphospholipid syndrome: A report of co-occurrence in three Malaysian family members.

Authors:  Md Asiful Islam; Kah Keng Wong; Teguh Haryo Sasongko; Siew Hua Gan; Jin Shyan Wong
Journal:  Eur J Rheumatol       Date:  2016-02-01

Review 8.  Renal involvement in antiphospholipid syndrome.

Authors:  Guillermo J Pons-Estel; Ricard Cervera
Journal:  Curr Rheumatol Rep       Date:  2014-02       Impact factor: 4.592

Review 9.  Current treatment of antiphospholipid syndrome: lights and shadows.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Nat Rev Rheumatol       Date:  2015-06-30       Impact factor: 20.543

Review 10.  The antiphospholipid syndrome: from pathophysiology to treatment.

Authors:  Simone Negrini; Fabrizio Pappalardo; Giuseppe Murdaca; Francesco Indiveri; Francesco Puppo
Journal:  Clin Exp Med       Date:  2016-06-22       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.